Andy Lin is a seasoned professional in the biotechnology and pharmaceutical industries, with extensive experience in process development and technical leadership. Lin's career includes roles as a Post Doc Scientist at Scios, Independent Consultant for various firms including Cellerant Therapeutics and Sangamo BioSciences, and significant positions at Genentech, where currently serving as VP Global Head of Individualized and Cell Therapy Development. Through previous roles, Lin has successfully managed multiple CMC projects, contributed to the accelerated BLA approval of polatuzumab vedotin (POLIVY), and developed core cell therapy technologies. Educational background includes a Ph.D. in Chemical Engineering from Northwestern University and a BS in Chemical Engineering from the University of California, Berkeley.
This person is not in the org chart
This person is not in any teams
This person is not in any offices